IP Library › Granted Patent US 8,105,568
Granted Patent B2
US 8,105,568 · App. 12/501,283 · Granted Jan 31, 2012

Vitamin receptor binding drug delivery conjugates

Assignee: Endocyte, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,105,568
App. No.
12/501,283
Granted
Jan 31, 2012
Kind
B2
Abstract

The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.

Claims (15)

1. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein D is selected from the group consisting of vinblastine, vincristine, and analogs and derivatives thereof.

2. The compound of claim 1 wherein D is deacetylvinblastine monohydrazide.

3. The compound of claim 1 of the formula

4. A pharmaceutical composition comprising a compound of claim 1 , and one or more carriers, diluents, or excipients, or a combination thereof.

5. The pharmaceutical composition of claim 4 wherein D is deacetylvinblastine monohydrazide.

6. The pharmaceutical composition of claim 4 wherein the compound is of the formula

7. A method for treating a cancer in a patient, the method comprising the step of administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 .

8. The method of claim 7 wherein the pharmaceutical composition further comprises one or more carriers, diluents, or excipients, or a combination thereof.

9. The method of claim 7 wherein D is deacetylvinblastine monohydrazide.

10. The method of claim 7 wherein the compound is of the formula

11. The method of claim 10 wherein the cancer is selected from the group consisting of oral, thyroid, endocrine, skin, gastric, esophageal, laryngeal, pancreatic, colon, bladder, bone, ovarian, cervical, uterine, breast, testicular, prostate, rectal, kidney, liver, and lung cancer.

12. The method of claim 10 wherein the cancer is ovarian cancer.

13. The method of claim 10 wherein the cancer is breast cancer.

14. The method of claim 10 wherein the cancer is lung cancer.

Continuity (5)
Continuation 10765336 · Jan 27, 2004
Provisional Application 60442845 · Jan 27, 2003
Provisional Application 60492119 · Aug 1, 2003
Provisional Application 60516188 · Oct 31, 2003
Related Publication 20100004276A1 · Jan 7, 2010